All Title Author
Keywords Abstract

D1 versus Modified D2 Gastrectomy for Ca Stomach—A Prospective and Comparative Study

DOI: 10.4236/ss.2016.71002, PP. 13-26

Keywords: Carcinoma Stomach, Gastrectomy Curative Resection, Lymphnode Dissection

Full-Text   Cite this paper   Add to My Lib


Background: Carcinoma stomach remains a major malignancy and accounts for 10.4% of cancer related deaths globally. Despite improvement in chemo-radiotherapy, surgery remains the primary curative modality with special emphasis on lymphadenectomy. However the extent of lymphadenectomy performed by surgeons all over the world differs. Generally speaking, in Japan and Korea, the standard curative protocol would entail a “D2” lymphadenectomy whereas in the western world it would be considered unnecessary and the standard protocol would entail a standard “D1” lymphadenectomy. Thus prompting a newer surgical therapy of modified D2 in dissection in which pancreas and spleen are preserved. Lymph nodes surrounding stomach are divided into 20 stations and these are classified into three groups depending upon the location of the primary tumour. Aims & Objectives: The aims and objectives are to compare: 1) operative time of modified D2 gastrectomy with that of D1 gastrectomy; 2) operative morbidity and mortality of modified D2 gastrectomy with that of D1 gastrectomy; 3) the disease recurrence between modified D2 & D1 gastrectomy. Materials & Method: The study entitled D1 versus modified D2 gastrectomy for Ca stomach—a prospective, comparative study was conducted in the Postgraduate Department of General Surgery, Government Medical College, Srinagar as a prospective, comparative study over a period of three years 2012-2014. Patients with resectable gastric cancer were taken as subjects for the study and were divided in 2 groups that were closely matched to avoid any bias. Assessment of both the groups was done in identical fashion as per standard protocol. One group underwent gastrectomy with D1 lymph node dissection whereas the other group underwent gastrectomy with a modified D2 lymph node dissection (spleen and pancreas preservation). The type of lymphadenectomy was decided on randomization (simple random sampling). Results: After comparing the two procedures, it was noted that: 1) modified D2 lymphadenectomy took on an average 2 hours more than D1 gastrectomy; 2) operative mortality was same in both the procedures. Operative morbidity was seen more in modified D2 group than D1 group however this difference was statistically insignificant; 3) number of recurrence was quite significant in D1 group but no recurrence was seen in modified D2 group. Conclusion: On the basis of the study, we recommend that modified D2 gastrectomy is a better procedure than D1


[1]  Jemal, A., Siegel, R., Ward, E., et al. (2008) Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96.
[2]  Kajitani, T. (1981) The General Rules for the Gastric Cancer Study in Surgery and pathology. Part I. Clinical Classification. Japanese Journal of Surgery, 11, 127-139.
[3]  Bonenkamp, J.J., Songun, I., Hermans, J., et al. (1995) Randomized Comparison of Morbidity after D1 and Modified D2 Dissection for Gastric Cancer in 996 Patients. The Lancet, 345, 745-748.
[4]  Cuschieri, A., Fayers, P., Fielding, J., et al. (1996) Postoperative Morbidity and Mortality after D1 Modified D2 Resections for Gastric Cancer: Preliminary Results of the MRC Randomized Controlled Surgical Trial. The Lancet, 347, 995-999.
[5]  Soga, J., Kobayahsi, K., Saito, J., Fukimaki, M. and Muto, T. (1979) The Role of Lymphadenectomy in Curative Surgery for Gastric Cancer. World Journal of Surgery, 3, 701-708.
[6]  Maruyama, K., Okabayashi, K. and Kinoshita, T. (1987) Progress in Gastric Cancer Surgery in Japan and Its Limits of Radicality. World Journal of Surgery, 11, 418-425.
[7]  Bonenkamp, J.J., Hermans, J., Sasasko, M., et al. (1993) Extended Lymph Node Dissection for Gastric Cancer. The New England Journal of Medicine, 340, 908-14.
[8]  Cushieri, A., Weeden, S., Fielding, J., et al. (1999) Patient Survival after D1 and Modified D2 Resections for Gastric cancer: Long Term Results of the MRC Randomized Surgical Trial. BJC, 79, 1522-1530.
[9]  Sue-Ling, H.M., Johnston, D., Martin, I.G., Dixon, M.F., Lansdown, M.R., McMahon, M.J. and Axon, A.T. (1993) Gastric Cancer: A Curable Disease in Britain. BMJ, 307, 591-596.
[10]  Griffith, J.P., Sue-Ling, H.M., Martin, I.G., Dixon, M.F., McMahon, M.J., Axon, A.T. and Johnston, D. (1995) Preservation of the Spleen Improves Survival after Radical Surgery for Gastric Cancer. Journal, 36, 684-690.
[11]  Songun, I., Putter, H., Kranenbarg, E.M.K., Sasako, M. and van de Velde, C.J.H. (2010) Surgical Treatment of Gastric Cancer: 15-Year Follow-Up Results of the Randomized Nationwide Dutch D1D2 Trial. The Lancet Oncology, 11, 439-449.
[12]  Degiuli, M., Sasako, M., Ponti, A., Soldati, T., Danese, F. and Calvo, F. (1998) Morbidity and Mortality after Modified D2 Gastrectomy for Gastric Cancer: Results of the Italian Gastric Cancer Study Group Prospective Multicenter Surgical Study. Journal of Clinical Oncology, 16, 1490-1493.
[13]  Wu, C.W., Hsiung, C.A., Lo, S.S., et al. (2006) Nodal Dissection for Patients with Gastric Cancer: A Randomized Controlled Trial. The Lancet Oncology, 7, 309-315.
[14]  Wu, C.W., Hsiung, C.A., Lo, S.S., Hsieh, M.C., Shia, L.T. and Whang-Peng, J. (2004) Randomized Clinical Trial of Morbidity after D1 and D3 Surgery for Gastric Cancer. British Journal of Surgery, 91, 283-287.
[15]  Degiuli, M., Sasasko, M., Ponti, A., et al. (2014) Morbidity and Mortality in Italian Gastric Cancer Study Group Randomized Clinical Trial of D1 versus Modified D2 Resection for Gastric Cancer. British Journal of Surgery, 101, 23-31.
[16]  Danielson, H., Kokkola, A., Kiviluoto, T., Siren, J., et al. (2007) Clinical Outcome after D1 versus D2-3 Gastrectomy for Treatment of Gastric Cancer. Scandinavian Journal of Surgery, 96, 35-40.
[17]  Lewis, W.G., Edwards, P., et al. (2002) D2 or Not D2? The Gastrectomy Question. Gastric Cancer, 5, 29-34.
[18]  Edwards, P., Blackshaw, G.R.J.C., Lewis, W.G., Barry, J.D., Allison, M.C. and Jones, D.R.B. (2004) Prospective Comparison of D1 vs. Modified D2 Gastrectomy for Carcinoma. British Journal of Cancer, 90, 1888-1892.
[19]  Strong, J.P., Baldizón, C., Salas, J., McMahan, C.A. and Mekbel, S. (1967) Mortality from Cancer Stomach in Costa Rica. Cancer, 20, 1173-1180.<1173::AID-CNCR2820200721>3.0.CO;2-C
[20]  Wanebo, H.J., Kennedy, B.J., Chmiel, J., Steele, G., Winchester, D. and Osteen, R. (1993) Cancer of Stomach. A Patient Care Study by American College of Surgeons. Annals of Surgery, 218, 583-592.
[21]  Huang, C.-M., Lin, J.-X., Zheng, C.-H., Li, P., Xie, J.-W. and Wang, J.-B. (2011) Impact of the Number of Dissected Lymph Nodes on Survival for Gastric Cancer after Distal Subtotal Gastrectomy. Gastroenterology Research and Practice, 2011, Article ID: 476014.
[22]  Methasate, A., Trakarnsanga, A., Akaraviputh, T., Chinsawangwathanakol, V. and Lohsiriwat, D. (2010) Lymph Node Metastasis in Gastric Cancer: Result of Modified D2 Dissection. Journal of the Medical Association of Thailand, 93, 310-317.
[23]  Sano, T., Sasako, M., Yamamoto, S., Nashimoto, A., Kurita, A., Hiratsuka, M., et al. (2004) Gastric Cancer Surgery: Morbidity and Mortality Results from a Prospective Randomized Controlled Trial Comparing Modified D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501. Journal of Clinical Oncology, 22, 2767-2773.
[24]  Kinoshita, T., Maruyama, K., Sasako, M. and Okajima, K. (1993) Treatment Results of Gastric Cancer Patients: Japanese Experience. In: Nishi, M., Ichikawa, H., Nakajima, T., Maruyama, K. and Tahara, E., Eds., Gastric Cancer, Springer, Tokyo, 319-330.
[25]  Cushieri, A., Fayers, P., Fielding, J., et al. (1996) Prospective Morbidity and Mortality after D1 and modified D2 Resections for Gastric Cancer: Preliminary Results of the MRC Randomized Controlled Surgical Trial. The Lancet, 347, 995-999.


comments powered by Disqus

Contact Us


微信:OALib Journal